







 Patient Name
 : OISHIKA CHOUDHURI
 Ref Dr.
 : Dr.MEDICAL OFFICER

 Age
 : 37 Y 2 M 2 D
 Collection Date
 : 07/Oct/2024 09:33AM

Gender : F Report Date : 07/Oct/2024 01:10PM



DEPARTMENT OF BIOCHEMISTRY

Test Name	Result	Bio Ref. Interval	Unit
CREATININE, BLOOD , GEL SERUM (Method:Jaffe, alkaline picrate, kinetic)	0.54	0.5-1.1	mg/dL
URIC ACID,BLOOD (Method:Uricase/Peroxidase)	4.3	2.6-6.0	mg/dL
CALCIUM,BLOOD (Method:Arsenazo III)	8.7	8.7-10.4	mg/dL
SODIUM,BLOOD (Method:ISE INDIRECT)	141	132 - 146	mEq/L
POTASSIUM,BLOOD (Method:ISE INDIRECT)	4.1	3.5-5.5	mEq/L
UREA,BLOOD (Method:Urease with GLDH)	19.3	19-49	mg/dL
PHOSPHORUS-INORGANIC,BLOOD (Method:Phosphomolybdate/UV)	3.7	2.4-5.1 mg/dL	mg/dL
THYROID PANEL (T3, T4, TSH), GEL SERUM			
T3-TOTAL (TRI IODOTHYRONINE) (Method:CLIA)	0.9	0.60-1.81 ng/ml	ng/ml
T4-TOTAL (THYROXINE) (Method:CLIA)	8.1	3.2-12.6	μg/dL
TSH (THYROID STIMULATING HORMONE) (Method:CLIA)	2.690	0.55-4.78	μIU/mL

Serum TSH levels exhibit a diurnal variation with the peak occurring during the night and the nadir, which approximates to 50% of the peak value, occurring between 1000 and 1600 hours.[1,2]

References:

1. Bugalho MJ, Domingues RS, Pinto AC, Garrao A, Catarino AL, Ferreira T, Limbert E and Sobrinho L. Detection of thyroglobulin mRNA transcripts in peripheral blood of

individuals with and without thyroid glands: evidence for thyroglobulin expression by blood cells. Eur J Endocrinol 2001;145:409-13.

2. Bellantone R, Lombardi CP, Bossola M, Ferrante A, Princi P, Boscherini M et al. Validity of thyroglobulin mRNA assay in peripheral blood of postoperative thyroid carcinoma patients in predicting tumor recurrence varies according to the histologic type: results of a prospective study. Cancer 2001;92:2273-9.

BIOLOGICAL REFERENCE INTERVAL: [ONLY FOR PREGNANT MOTHERS]

Trimester specific TSH LEVELS during pregnancy:

FIRST TRIMESTER: 0.10 – 3.00 μ IU/mL SECOND TRIMESTER: 0.20 -3.50 μ IU/mL THIRD TRIMESTER: 0.30 -3.50 μ IU/mL

References:

1. Erik K. Alexander, Elizabeth N. Pearce, Gregory A. Brent, Rosalind S. Brown, Herbert Chen, Chrysoula Dosiou, William A. Grobman, Peter Laurberg, John H. Lazarus, Susan J. Mandel, Robin P. Peeters, and Scott Sullivan. Thyroid. Mar 2017.315-389. http://doi.org/10.1089/thy.2016.0457
2. Kalra S, Agarwal S, Aggarwal R, Ranabir S. Trimester-specific thyroid-stimulating hormone: An indian perspective. Indian J Endocr Metab 2018;22:1-4.









: OISHIKA CHOUDHURI

Age : 37 Y 2 M 2 D

Gender : F

Patient Name

Lab Add. : Newtown,Kolkata-700156

Ref Dr. : Dr.MEDICAL OFFICER

Collection Date : 07/Oct/2024 09:33AM

Report Date : 07/Oct/2024 01:10PM



DEPARTMENT OF BIOCHEMISTRY

Test Name	Result	Bio Ref. Interval	Unit	
GLUCOSE,FASTING (Method:Gluc Oxidase Trinder)	96	Impaired Fasting-100-125 .~Diabetes- >= 126.~Fasting is defined as no caloric intake for at least 8 hours.	mg/dL	

In the absence of unequivocal hyperglycemia, diagnosis requires two abnormal test results from the same sample or in two separate test samples.

Reference :

ADA Standards of Medical Care in Diabetes – 2020. Diabetes Care Volume 43, Supplement 1.

*** End Of Report ***

Dr Neepa Chowdhury MBBS, MD(Biochemistry) SECTION DIRECTOR AND SENIOR CONSULTANT BIOCHEMIST Reg no. WBMC 62456

Lab No. : DUN/07-10-2024/SR9754850









Patient Name : OISHIKA CHOUDHURI

Age : 37 Y 2 M 2 D

Gender : F

Lab Add. : Newtown,Kolkata-700156

Ref Dr. : Dr.MEDICAL OFFICER

Collection Date : 07/Oct/2024 09:33AM

Report Date : 07/Oct/2024 01:03PM

DEPARTMENT OF BIOCHEMISTRY

Test Name Result Bio Ref. Interval Unit	t
---	---

CHLORIDE,BLOOD 108 99-109 mEq/L (Method:ISE INDIRECT)

*** End Of Report ***

DR. ANANNYA GHOSH MBBS, MD (Biochemistry) Consultant Biochemist Reg No. WBMC 73007

Lab No. : DUN/07-10-2024/SR9754850 Page 3 of 13



Test Name







Unit

Lab No. : DUN/07-10-2024/SR9754850 Lab Add. : Newtown, Kolkata-700156

Patient Name : OISHIKA CHOUDHURI Ref Dr. : Dr.MEDICAL OFFICER : 37 Y 2 M 2 D **Collection Date** : 07/Oct/2024 09:33AM Age Gender : F Report Date : 07/Oct/2024 01:14PM

Result



DEPARTMENT OF BIOCHEMISTRY

TOTAL PROTEIN [BLOOD] ALB	GLO RATIO , .			
TOTAL PROTEIN (Method:BIURET METHOD)	7.1	5.7-8.2 g/dL	g/dL	
ALBUMIN	4	3.2-4.8 g/dL	g/dL	

(Method:BCG Dye Binding) **GLOBULIN** 3.1 1.8-3.2 g/dl (Method:Calculated)

AG Ratio 1.29 1.0 - 2.5(Method:Calculated)

GLYCATED HAEMOGLOBIN (HBA1C), EDTA WHOLE BLOOD

GLYCATED HEMOGLOBIN (HBA1C) 4.8 ***FOR BIOLOGICAL REFERENCE %

> INTERVAL DETAILS, PLEASE REFER TO THE BELOW MENTIONED REMARKS/NOTE WITH ADDITIONAL CLINICAL

INFORMATION ***

Bio Ref. Interval

HbA1c (IFCC) 29 mmol/mol (Method:HPLC)

Clinical Information and Laboratory clinical interpretation on Biological Reference Interval:

Low risk / Normal / non-diabetic : <5.7% (NGSP) / < 39 mmol/mol (IFCC) Pre-diabetes/High risk of Diabetes : 5.7%- 6.4% (NGSP) / 39 - < 48 mmol/mol (IFCC) : >/= 6.5% (NGSP) / > 48 mmol/mol (IFCC) Diabetics-HbA1c level

Analyzer used :- Bio-Rad-VARIANT TURBO 2.0

Method: HPLC Cation Exchange

Recommendations for glycemic targets

- Ø Patients should use self-monitoring of blood glucose (SMBG) and HbA1c levels to assess glycemic control.
- Ø The timing and frequency of SMBG should be tailored based on patients' individual treatment, needs, and goals.
- Ø Patients should undergo HbA1c testing at least twice a year if they are meeting treatment goals and have stable glycemic control.
- Ø If a patient changes treatment plans or does not meet his or her glycemic goals, HbA1c testing should be done quarterly.
- Ø For most adults who are not pregnant, HbA1c levels should be <7% to help reduce microvascular complications and macrovascular disease . Action suggested >8% as it indicates poor control.
- Ø Some patients may benefit from HbA1c goals that are stringent.

Result alterations in the estimation has been established in many circumstances, such as after acute/ chronic blood loss, for example, after $surgery, blood\ transfusions, he molytic\ anemia, or\ high\ erythrocyte\ turnover;\ vitamin\ B_{12}/\ folate\ deficiency,\ presence\ of\ chronic\ renal\ or\ liver$ disease; after administration of high-dose vitamin E / C; or erythropoietin treatment.

Reference: Glycated hemoglobin monitoring BMJ 2006; 333;586-8

- 1. Chamberlain JJ, Rhinehart AS, Shaefer CF, et al. Diagnosis and management of diabetes: synopsis of the 2016 American Diabetes Association Standards of Medical Care in Diabetes. Ann Intern Med. Published online 1 March 2016. doi:10.7326/M15-3016.
 2. Mosca A, Goodall I, Hoshino T, Jeppsson JO, John WG, Little RR, Miedema K, Myers GL, Reinauer H, Sacks DB, Weykamp CW. International Federation of Clinical Chemistry and Laboratory Medicine, IFCC Scientific Division. Global standardization of glycated hemoglobin measurement: the position of the IFCC Working Group. Clin Chem Lab Med. 2007; 45(8):1077-1080.

PDF Attached

LIPID PROFILE, GEL SERUM			
CHOLESTEROL-TOTAL (Method:Enzymatic)	146	Desirable: < 200 mg/dL Borderline high: 200-239 mg/dL High: > or =240 mg/dL	mg/dL
TRIGLYCERIDES (Method:GPO-Trinder)	65	Normal:: < 150, BorderlineHigh::150-199, High:: 200-499, VeryHigh::>500	mg/dL
HDL CHOLESTEROL	49	< 40 - Low	mg/dl
	Lab No. :	DUN/07-10-2024/SR9754850	Page 4 of 13









Patient Name : OISHIKA CHOUDHURI

Age : 37 Y 2 M 2 D

Gender : F

Lab Add. : Newtown,Kolkata-700156

Ref Dr. : Dr.MEDICAL OFFICER

Collection Date : 07/Oct/2024 09:33AM

Report Date : 07/Oct/2024 01:14PM



DEPARTMENT OF BIOCHEMISTRY

Test Name	Result	Bio Ref. Interval	Unit
(Method:Elimination/catalase)		40-59- Optimum 60 - High	
LDL CHOLESTEROL DIRECT (Method:Elimination / Catalase)	86	OPTIMAL: <100 mg/dL, Near optimal/ above optimal: 100- 129 mg/dL, Borderline high: 130-159 mg/dL, High: 160-189 mg/dL, Very high: >=190 mg/dL	mg/dL
VLDL (Method:Calculated)	11	< 40 mg/dl	mg/dl
CHOL HDL Ratio (Method:Calculated)	3	LOW RISK 3.3-4.4 AVERAGE RISK 4.47-7.1 MODERATE RISK 7.1-11.0 HIGH RISK >11.0	

Reference: National Cholesterol Education Program. Executive summary of the third report of The National Cholesterol Education Program (NCEP) Expert Panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA. May 16 2001;285(19):2486-97.

*** End Of Report ***

Dr. Sudeshna Baral M.B.B.S MD. (Biochemistry) (Consultant Biochemist) Reg No. WBMC 64124

Lab No. : DUN/07-10-2024/SR9754850









Patient Name : OISHIKA CHOUDHURI

Age : 37 Y 2 M 2 D

Gender : F

Lab Add. : Newtown,Kolkata-700156

Ref Dr. : Dr.MEDICAL OFFICER

Report Date : 07/Oct/2024 12:48PM

: 07/Oct/2024 09:33AM

Collection Date



DEPARTMENT OF HAEMATOLOGY

F	Test Name	Result	Bio Ref. Interval	Unit

CBC WITH PLATELET (THROMBOCYTE)	COUNT . FDTA WHOLF BLO	OD	
HEMOGLOBIN (Method:PHOTOMETRIC)	12.1	12 - 15	g/dL
WBC (Method:DC detection method)	7	4 - 10	*10^3/µL
RBC (Method:DC detection method)	4.22	3.8 - 4.8	*10^6/µL
PLATELET (THROMBOCYTE) COUNT (Method:DC detection method/Microscopy)	182	150 - 450*10^3	*10^3/µL
DIFFERENTIAL COUNT			
NEUTROPHILS (Method:Flowcytometry/Microscopy)	62	40 - 80	%
LYMPHOCYTES (Method:Flowcytometry/Microscopy)	26	20 - 40	%
MONOCYTES (Method:Flowcytometry/Microscopy)	08	2 - 10	%
EOSINOPHILS (Method:Flowcytometry/Microscopy)	04	1 - 6	%
BASOPHILS (Method:Flowcytometry/Microscopy) CBC SUBGROUP	00	0-0.9	%
HEMATOCRIT / PCV (Method:Calculated)	38.3	36 - 46 %	%
MCV (Method:Calculated)	90.7	83 - 101 fl	fl
MCH (Method:Calculated)	28.6	27 - 32 pg	pg
MCHC (Method:Calculated)	31.6	31.5-34.5 gm/dl	gm/dl
RDW - RED CELL DISTRIBUTION WIDTH (Method:Calculated)	13.3	11.6-14%	%
PDW-PLATELET DISTRIBUTION WIDTH (Method:Calculated)	33.0	8.3 - 25 fL	fL
MPV-MEAN PLATELET VOLUME (Method:Calculated)	13.7	7.5 - 11.5 fl	

BLOOD GROUP ABO+RH [GEL METHOD], EDTA WHOLE BLOOD

ABO O

(Method:Gel Card)

RH POSITIVE

(Method:Gel Card)

TECHNOLOGY USED: GEL METHOD

ADVANTAGES:

- Gel card allows simultaneous forward and reverse grouping.
- Card is scanned and record is preserved for future reference.
- Allows identification of Bombay blood group.
- Daily quality controls are run allowing accurate monitoring.

Historical records check not performed.

ESR (ERYTHROCYTE SEDIMENTATION RATE), EDTA WHOLE BLOOD

 1stHour
 08
 0.00 - 20.00 mm/hr
 mm/hr

 (Method:Westergren)
 mm/hr
 mm/hr
 mm/hr

Lab No. : DUN/07-10-2024/SR9754850 Page 6 of 13









Patient Name : OISHIKA CHOUDHURI

Age : 37 Y 2 M 2 D

Gender : F

Lab Add. : Newtown,Kolkata-700156

Ref Dr. : Dr.MEDICAL OFFICER

Collection Date : 07/Oct/2024 09:33AM

Report Date : 07/Oct/2024 12:48PM

DEPARTMENT OF HAEMATOLOGY

Test Name Result Bio Ref. Interval Unit

*** End Of Report ***

Dr. KAUSHIK DEY MD (PATHOLOGY)

Page 7 of 13

CONSULTANT PATHOLOGIST Reg No. WBMC 66405

E-mail: info@surakshanet.com | Website: www.surakshanet.com



Patient Name : OISHIKA CHOUDHURI Ref Dr. : Dr.MEDICAL OFFICER

Age : 37 Y 2 M 2 D Collection Date

Gender : F Report Date : 07/Oct/2024 04:31PM



DEPARTMENT OF X-RAY

X-RAY REPORT OF CHEST (PA)

Lab Add.

FINDINGS:

Mildly increased vascular markings seen at both parahilar and paracardiac regions.

Mediastinum is in central position. Trachea is in midline.

Domes of diaphragm are smoothly outlined. Position is within normal limits.

Both costo-phrenic angles are clear.

Cardiac shadow appears normal.

*** End Of Report ***

DR. SUBRATA SANYAL MBBS (CAL), DMRD (CAL). CONSULTANT SONOLOGIST AND RADIOLOGIST.

Page 8 of 13

Lab No. : DUN/07-10-2024/SR9754850









 Patient Name
 : OISHIKA CHOUDHURI
 Ref Dr.
 : Dr.MEDICAL OFFICER

 Age
 : 37 Y 2 M 2 D
 Collection Date
 : 07/Oct/2024 09:40AM

 Gender
 : F
 Report Date
 : 07/Oct/2024 03:04PM



DEPARTMENT OF CLINICAL PATHOLOGY

Test Name Result Bio Ref. Interval Unit

PHYSICAL EXAMINATION				
COLOUR	PALE YELLOW			
APPEARANCE	HAZY			
CHEMICAL EXAMINATION				
pH (Method:Dipstick (triple indicator method))	7.0	4.6 - 8.0		
SPECIFIC GRAVITY	1.010	1.005 - 1.030		
(Method:Dipstick (ion concentration method)) PROTEIN (Method:Dipstick (protein error of pH	NOT DETECTED	NOT DETECTED		
dicators)/Manual) GLUCOSE (Method:Dipstick(glucose-oxidase-peroxidase	NOT DETECTED	NOT DETECTED		
ethod)/Manual) KETONES (ACETOACETIC ACID, ACETONE)	NOT DETECTED	NOT DETECTED		
(Method:Dipstick (Legals test)/Manual) BLOOD (Method:Dipstick (pseudoperoxidase reaction))	NOT DETECTED	NOT DETECTED		
BILIRUBIN	NEGATIVE	NEGATIVE		
(Method:Dipstick (azo-diazo reaction)/Manual) UROBILINOGEN	NEGATIVE	NEGATIVE		
(Method:Dipstick (diazonium ion reaction)/Manual) NITRITE	NEGATIVE	NEGATIVE		
(Method:Dipstick (Griess test)) LEUCOCYTE ESTERASE (Method:Dipstick (ester hydrolysis reaction)) MICROSCOPIC EXAMINATION	POSITIVE(+)	NEGATIVE		
LEUKOCYTES (PUS CELLS)	3-5	0-5	/hpf	
(Method:Microscopy) EPITHELIAL CELLS (Method:Microscopy)	12-15	0-5	/hpf	
(Method:Microscopy) RED BLOOD CELLS (Method:Microscopy)	NOT DETECTED	0-2	/hpf	
CAST (Method:Microscopy)	NOT DETECTED	NOT DETECTED		
CRYSTALS (Method:Microscopy)	NOT DETECTED	NOT DETECTED		
BACTERIA (Method:Microscopy)	PRESENT(++)	NOT DETECTED		
YEAST (Method:Microscopy)	NOT DETECTED	NOT DETECTED		

Note:

- $1. \ All \ urine \ samples \ are \ checked \ for \ adequacy \ and \ suitability \ before \ examination.$
- 2. Analysis by urine analyzer of dipstick is based on reflectance photometry principle. Abnormal results of chemical examinations are confirmed by manual methods.
- 3. The first voided morning clean-catch midstream urine sample is the specimen of choice for chemical and microscopic analysis.
- 4. Negative nitrite test does not exclude urinary tract infections.
- 5. Trace proteinuria can be seen in many physiological conditions like exercise, pregnancy, prolonged recumbency etc.
- 6. False positive results for glucose, protein, nitrite, urobilinogen, bilirubin can occur due to use of certain drugs, therapeutic dyes, ascorbic acid, cleaning agents used in urine collection container.
- 7. Discrepancy between results of leukocyte esterase and blood obtained by chemical methods with corresponding pus cell and red blood cell count by microscopy can occur due to cell lysis.
- 8. Contamination from perineum and vaginal discharge should be avoided during collection, which may falsely elevate epithelial cell count and show presence of bacteria

 Lab No. : DUN/07-10-2024/SR9754850 Page 9 of 13









: DUN/07-10-2024/SR9754850 Lab No.

Patient Name : OISHIKA CHOUDHURI

Age : 37 Y 2 M 2 D

Gender : F Lab Add. : Newtown, Kolkata-700156

Ref Dr. : Dr.MEDICAL OFFICER

Collection Date : 07/Oct/2024 09:40AM

: 07/Oct/2024 03:04PM Report Date

DEPARTMENT OF CLINICAL PATHOLOGY

Bio Ref. Interval **Test Name** Result Unit

and/or yeast in the urine.

*** End Of Report ***

Kaushik Dr. KAUSHIK DEY MD (PATHOLOGY) CONSULTANT PATHOLOGIST

Reg No. WBMC 66405

E-mail: info@surakshanet.com | Website: www.surakshanet.com



Patient Name : OISHIKA CHOUDHURI Ref Dr. : Dr.MEDICAL OFFICER

: 37 Y 2 M 2 D **Collection Date** Age

: F : 07/Oct/2024 04:11PM Gender Report Date



DEPARTMENT OF CARDIOLOGY

Lab Add.

		E.C.G. REPOR	RT
DATA HEART RATE	63	Bpm	
PR INTERVAL	166	Ms	
QRS DURATION	92	Ms	
QT INTERVAL	392	Ms	
QTC INTERVAL	402	Ms	
AXIS P WAVE	52	Degree	
QRS WAVE	57	Degree	
T WAVE	39	Degree	
IMPRESSION	:	Sinus arrhythmia otherwise normal ECG.	

*** End Of Report ***

Department of Non-invasive Cardiology

DUN/07-10-2024/SR9754850 Page 11 of 13 Lab No.



Patient Name : OISHIKA CHOUDHURI Ref Dr. : Dr.MEDICAL OFFICER

Age : 37 Y 2 M 2 D Collection Date :

Gender : F Report Date : 07/Oct/2024 05:45PM



DEPARTMENT OF ULTRASONOGRAPHY

DEPARTMENT OF ULTRASONOGRAPHY

Lab Add.

REPORT ON EXAMINATION OF WHOLE ABDOMEN

LIVER: Normal in shape, size (14.3 cm) and parenchymal echopattern. No focal lesion of altered echogenicity is seen. Intrahepatic biliary radicles are not dilated. The portal vein branches and hepatic veins are normal.

GALL BLADDER: Well distended lumen shows no intra-luminal calculus or mass. Wall thickness is normal. No pericholecystic collection or mass formation is noted.

PORTA HEPATIS: The portal vein (1.00 cm) is normal in caliber with clear lumen. The common bile duct is normal in caliber. Visualized lumen is clear till visualised extent. Common bile duct measures approx 0.32 cm in diameter. *Extreme lower end of common bile duct is not visualised due to bowel gas shadow.*

PANCREAS: It is normal in shape, size and echopattern. Main pancreatic duct is not dilated. No focal lesion of altered echogenicity is seen. The peripancreatic region shows no abnormal fluid collection.

SPLEEN: It is normal in shape, size (9.0 cm) and shows homogeneous echopattern. No focal lesion is seen. No abnormal venous dilatation is seen in the splenic hilum.

KIDNEYS: Both Kidneys are normal in shape, size and position. Cortical echogenicity and thickness are normal with normal cortico-medullary differentiation in both kidneys. No calculus, hydronephrosis or mass is noted. The perinephric region shows no abnormal fluid collection.

RIGHT KIDNEY measures 10.6 cm LEFT KIDNEY measures 9.0 cm

URETER: Both ureters are not dilated. No calculus is noted in either side.

PERITONEUM & RETROPERITONEUM: The aorta and IVC are normal. Lymph nodes are not enlarged. No free fluid is seen in peritoneum.

URINARY BLADDER: It is adequately distended providing optimum scanning window. The lumen is clear and wall thickness is normal.

<u>UTERUS:</u> It is normal in size (6.8 x 3.3 x 4.2 cm), shape and echopattern. **One 12 x 9 mm small fibroid noted at anterior wall of uterus**. Endometrial echo is in midline. Double layer of endometrial echo measures 0.52 cm. Endometrial cavity is empty. Cervix is normal.

ADNEXA: No adnexal SOL is noted.

OVARIES: Bilateral ovaries are normal in size but show mild polycystic changes.

Right ovary measures 3.4 x 1.4 x 3.0 cm. & volume is 8.1 cc.

Left ovary measures 3.1 x 1.8 x 2.5 cm & volume is 7.8 cc,

POD: No fluid is seen.

IMPRESSION:

Small uterine fibroid.

Bilateral mild polycystic changes.

Lab No.: DUN/07-10-2024/SR9754850 Page 12 of 13



> : OISHIKA CHOUDHURI Ref Dr. : Dr.MEDICAL OFFICER

Lab Add.

Age : 37 Y 2 M 2 D **Collection Date**

:F : 07/Oct/2024 05:45PM Gender Report Date



DEPARTMENT OF ULTRASONOGRAPHY

Please correlate clinically.

Patient Name

Kindly note

- Ultrasound is not the modality of choice to rule out subtle bowel lesion.
- Please Intimate us for any typing mistakes and send the report for correction within 7 days.
- The science of Radiological diagnosis is based on the interpretation of various shadows produced by both the normal and abnormal tissues and are not always conclusive. Further biochemical and radiological investigation & clinical correlation is required to enable the clinician to reach the final diagnosis.

The report and films are not valid for medico-legal purpose.

Patient Identity not verified.

DR. NAMRATA CHATTERJEE MBBS,CONSULTANT SONOLOGIST

Reg No: 79092

Page 13 of 13 Lab No. DUN/07-10-2024/SR9754850

SURAKSHA DIAGNOSTIC, RAJARHAT, KOLKATA BIO-RAD VARIANT-II TURBO CDM5.4 SN-15893

PATIENT REPORT V2TURBO A1c 2.0

Patient Data Analysis Data

Sample ID: Analysis Performed: E02132913149 10/07/2024 12:48:12

Patient ID: Injection Number: SR9754850 9668 OISHIKA CHOUDHU Run Number: 147 Name: Rack ID: 0004 Physician: F

DOB: Report Generated: 10/07/2024 13:01:35

Tube Number:

Operator ID: **ASIT**

Comments:

Sex:

	NGSP		Retention	Peak
Peak Name	%	Area %	Time (min)	Area
A1a		0.6	0.136	10866
Unknown		0.6	0.164	10828
A1b		0.9	0.227	18041
F		0.8	0.273	15193
LA1c		1.9	0.395	36208
A1c	4.8		0.503	79392
P3		3.2	0.778	61671
P4		1.1	0.863	20889
Ao		86.8	0.993	1666528

Total Area: 1,919,616

3

HbA1c (IFCC) = 29 mmol/mol HbA1c (NGSP) = 4.8 %

